How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,244 results for

HIPAA

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis

have no known allergy to riluzole or inactive ingredients* in ROSF. Subjects or subject's legally authorized representative must be willing and able to complete informed consent/assent and HIPAA authorization. Ability to comprehend and be informed of the nature of the study, as assessed by the Primary or Sub-Investigator. Subjects prescribed to take riluzole at or before the time of first dose. (The study is open to subjects currently taking riluzole at screening, subjects who are not currently

2018 Clinical Trials

102. Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load

products. Patients with full-thickness wounds that are not yet extending to the bone or tendon. Patients with wounds present for at least 4 weeks, but no longer than one year. Patients with initial bacterial load greater than or equal to 104 colony forming units (CFUs), but less than or equal to 106 CFUs. Patients who have voluntarily signed the informed consent form, including HIPAA Authorization. Exclusion Criteria: Patients who are younger than 18 years of age. Patients with autoimmune conditions

2018 Clinical Trials

103. Autologous, Culture-Expanded Mesenchymal Stromal Cells for Degenerative Disc Disease

, diagnostic imaging, and follow-up visits and assessments. Can provide written informed consent and complete HIPAA documentation after the nature of the study is fully explained and prior to any study-related procedure. Exclusion Criteria: Subjects who are pregnant or nursing, or subjects planning to become pregnant in the first 24 months post-treatment. If a subject becomes pregnant during the study, the subject will remain in the study and only the requirement for radiation (x-ray or MRI

2018 Clinical Trials

104. Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers

-cigarettes: An Evidence Update. A report commissioned by Public Health England. Available at: https://www.gov.uk/government/uploads/system/uploads/ attachment_data/file/457102/Ecigarettes_an_evidence_update_A_report_commissioned_by_ Public_Health_England_FINAL.pdf (Aug 2015). Other Publications: HIPAA Privacy Rule. Information for Researchers. De-identifying Protected Health Information Under the Privacy Rule. U.S. Department of Health and Human Services. NIH (Feb 2007). Available at: http

2018 Clinical Trials

105. Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)

greater than one hour either for clinical or research purposes within 3 hrs of the proposed PET-MRI examination. Participant will be fully informed and has personally signed and dated the written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) provisions Exclusion Criteria: Subjects for whom exposure to a strong magnetic field would be a health risk (e.g., subjects with cardiac pacemakers or non-MR compatible metallic implants) Women who are pregnant. Subjects who

2018 Clinical Trials

106. Lutronic Infini and LaseMD Systems in Combination Treatment

informed consent and HIPAA authorization prior to performance of any study-related procedure. Exclusion Criteria: Presence of an active systemic or local skin disease that may affect wound healing. History of keloids or poor wound healing. Severe solar elastosis. Excessive subcutaneous fat in the area(s) to be treated. Excessive skin laxity on the area(s) to be treated. Significant scarring in the area(s) to be treated that would interfere with assessing results. Open wounds or lesions in the area(s

2018 Clinical Trials

107. Lutronic LaseMD for Treatment of Benign Pigmented Lesions

and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure. Exclusion Criteria: Presence of an active systemic or local skin disease that may affect wound healing. History of keloids or poor wound healing. Significant scarring in the area(s) to be treated that would interfere with assessing results. Open wounds or lesions in the area(s) to be treated. Inability to understand the protocol or to give informed consent. Microdermabrasion

2018 Clinical Trials

108. Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride

Portability and Accountability Act (HIPAA) documentation. Female subjects of childbearing potential must have a negative serum pregnancy test at screening. human chorionic gonadotropin levels will be assessed for all women of childbearing years prior to the procedure. Exclusion Criteria: Severe septicemia or severe infection in the 4 weeks prior to study entry; The subject has a baseline NIHSS > 1 or modified Rankin Scale > 1. Active participation in other research therapy for cardiovascular repair

2018 Clinical Trials

109. Mobile Devices as Educational Skin History Tools

or other drug treatment facilities and therefore considered prisoners Patients will also be excluded if they are incompetent to provide informed consent and HIPAA authorization. If the area being operated on is of the genitals or breasts If the area being operated on is of the face, and photos of the area cannot be cropped or the eyes cannot be covered sufficiently such that photos are non-identifying Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2018 Clinical Trials

110. Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study

baseline period. Note: Each seizure within a cluster may be counted as separate seizures. 5. 12 years of age or older. 6. Subject is a male or non-pregnant female adequately protected from conception. Females of childbearing potential must use an acceptable method of birth control. 7. Provide written informed consent-assent/Health Insurance Portability and Accountability Act (HIPAA) authorization and self-reported measures with minimal assistance as determined by the investigator. Exclusion Criteria

2018 Clinical Trials

111. Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

More Information Go to Layout table for additonal information Responsible Party: HonorHealth Research Institute ClinicalTrials.gov Identifier: Other Study ID Numbers: SU2C HRI NPG-002 First Posted: January 25, 2018 Last Update Posted: February 21, 2019 Last Verified: February 2019 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Plan Description: If the study site is a 'covered site' under the definitions of the Health Insurance Portability and Accounting Act (HIPAA

2018 Clinical Trials

112. Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information. Males aged 18 years of age and above Histological or cytologic proof of adenocarcinoma of the prostate Germline mutation in one or more homologous recombination DNA-repair genes (BRCA1, BRCA2, ATM, CHEK2, NBN, RAD50, RAD51C, RAD51D, PALB2, MRE11, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM

2018 Clinical Trials

113. Post-Exercise Cardiovascular Responses Following Energy Drink Consumption

the study or consent process will be excluded from the study due to unavailability of medical qualified translator at all times during the study. If the subject refuses to sign the informed consent document or HIPAA Authorization, they will be excluded as well. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer

2018 Clinical Trials

114. A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, where applicable, prior to any study-related procedures; participants will be asked to give written or verbal assent according to local requirements Subject has a centrally confirmed (by TRiNDS central genetic counselor[s]) diagnosis of DMD as defined as: Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, OR Identifiable mutation

2018 Clinical Trials

115. Neural Basis of Eating Behavior in Abstinent Smokers

than 100 lifetime cigarettes and not even a puff of a cigarette for a minimum of 2 years. Smoking status of non-smokers will be confirmed by CO less than 5ppm. They will be matched to the smoker group on age, sex, and education. Plan to live in the area for the duration of the study (i.e. ~8 weeks/2 months). Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form. Smokers who wish to make a permanent

2018 Clinical Trials

116. Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

the study.] ii. Subjects with moderate plaque type psoriasis who have been started on commercial Otezla within the last 10 days. iii. Physician Global Assessment (PGA) score of 3. iv. Able to understand study requirements and sign Informed Consent/HIPAA forms. Exclusion Criteria: I. Female subjects who are pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control, or male subjects planning a pregnancy with their spouse or partner while

2018 Clinical Trials

117. Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

for analysis. Individuals seeking use of these data should contact the study chair. A data sharing contract for a HIPAA limited dataset will need to be executed prior to data sharing. Supporting Materials: Clinical Study Report (CSR) Time Frame: Available as requested. Data will be archived indefinitely for research purposes. Access Criteria: Individuals seeking use of these data should contact the study chair. Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies

2018 Clinical Trials

118. Restoring Hand Function Utilizing Nerve Transfers in Persons With Cervical Spinal Cord Injuries

Physically and mentally willing and able to comply with study protocol Lives in the immediate area and has no plans to relocate Provides informed consent and HIPAA release of medical information Exclusion Criteria: Active infection Any return or ongoing clinical recovery of distal motor function within 6 months after injury Physically/mentally compromised Systemic disease that would affect the patient's welfare or the research study Immunologically suppressed or immunocompromised Currently undergoing

2018 Clinical Trials

119. Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Written informed consent and HIPAA authorization (applies to covered entities in the USA only) obtained from the subject/legal representative prior to performing any protocol-related

2018 Clinical Trials

120. Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Subject must meet all the following applicable inclusion criteria to participate in this study: Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Age ≥ 18 years at the time of consent. Eastern Cooperative Oncology Group (ECOG

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>